Financial Performance - The company's revenue for the third quarter reached ¥83,642,998, representing a year-on-year increase of 54.38%[3] - The total profit for the period was a loss of ¥2,427,622.54, while the profit for the year-to-date was ¥751,211.30, reflecting a decrease of 83.68% compared to the previous year[3] - The net profit attributable to shareholders was ¥2,791,600.17 for the quarter, with a year-to-date net profit of ¥8,836,659.11, showing an increase of 15.82%[3] - Total operating revenue for the first three quarters of 2025 reached ¥224,643,650.85, an increase of 2.5% compared to ¥219,574,032.71 in the same period of 2024[20] - The company reported a net loss of ¥5,462,086.29 for the first three quarters of 2025, compared to a net profit of ¥2,032,527.91 in the same period of 2024[21] - Operating profit turned negative at -¥999,815.58, a significant decline from a profit of ¥5,295,471.14 in the previous year[20] Assets and Liabilities - The company's total assets increased by 13.70% year-on-year, reaching ¥1,197,742,892.15[4] - The company's total assets increased to ¥1,197,742,892.15, up from ¥1,053,411,101.81 year-over-year[17] - Total liabilities rose to ¥357,600,902.10, compared to ¥207,957,231.30 in the previous year, indicating a substantial increase in financial obligations[17] - The equity attributable to shareholders decreased slightly to ¥805,700,841.25 from ¥810,050,019.65 year-over-year[17] Cash Flow - The net cash flow from operating activities for the year-to-date was ¥126,246,149.55, an increase of 195.71% compared to the previous year[3] - Cash inflow from operating activities for the first three quarters of 2025 reached approximately $404.46 million, an increase from $376.77 million in the same period of 2024, representing a growth of about 7.3%[23] - The net cash flow from operating activities significantly improved to $126.25 million in 2025, compared to $42.69 million in 2024, indicating a substantial increase of approximately 195.5%[23] - Total cash inflow from investment activities was $712.46 million in 2025, a significant rise from $107.08 million in 2024, marking an increase of about 564.5%[24] - Cash outflow for investments surged to $867.87 million in 2025, compared to $282.70 million in 2024, reflecting an increase of approximately 207.5%[24] - The net cash flow from investment activities was negative at -$155.41 million in 2025, slightly improved from -$175.62 million in 2024[24] - The net cash flow from financing activities was positive at $21.74 million in 2025, contrasting with a negative flow of -$59.49 million in 2024[24] Research and Development - Research and development expenses totaled ¥13,136,170.78 for the quarter, accounting for 15.71% of revenue, a decrease of 0.09 percentage points compared to the previous year[4] - Research and development expenses for the first three quarters were ¥31,113,408.83, up from ¥28,854,806.83 in the same period last year, reflecting a focus on innovation[20] Shareholder Information - The top shareholder, Lin Junhua, holds 47.15% of the shares, while the second-largest shareholder, Chen Wanshun, holds 14.89%[12] - The company has a total of 4,528 preferred shareholders at the end of the reporting period[11] - The company has not reported any changes in major shareholders or their participation in securities lending activities during the reporting period[13] Market and Competition - The company faced intensified competition in the domestic market for safety infusion equipment, impacting gross margins and overall profitability[8] - The increase in revenue was attributed to orderly production according to order cycles, with unrecognized revenue of ¥7,645.20 pending confirmation[8] Other Information - The company has not disclosed any new product developments or technological advancements in the current reporting period[14] - There are no significant changes in the company's operational strategies or market expansion plans mentioned in the report[14] - The company will not apply new accounting standards or interpretations starting from 2025[25]

广发证券股份有限公司 关于迈得医疗工业设备股份有限公司 募投项目延期的核查意见 广发证券股份有限公司（以下简称"广发证券"或"保荐机构"）作为迈得 医疗工业设备股份有限公司（以下简称"迈得医疗"或"公司"）首次公开发行 股票并在科创板上市的保荐机构，根据《证券发行上市保荐业务管理办法》《上 市公司募集资金监管规则》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》《上海证券交易所科创板股票上市规则》等法律法规的规定， 对迈得医疗募投项目延期的事项进行了审慎核查，核查情况如下： 一、募集资金基本情况 根据中国证券监督管理委员会《关于同意迈得医疗工业设备股份有限公司首 次公开发行股票注册的批复》（证监许可〔2019〕2019 号），中国证券监督管理委 员会同意公司首次公开发行股票的注册申请。公司首次公开发行人民币普通股 （A 股）股票 2,090 万股，每股面值人民币 1.00 元，每股发行价格 24.79 元，募 集资金总额为人民币 51,811.10 万元，扣除发行费用人民币 6,075.96 万元（不含 税）后，募集资金净额为人民币 45,735.14 万元。该募集资金已于 2019 年 1 ...

迈得医疗公告，第三季度营收为8364.3万元，同比增长54.38%；净利润为279.16万元。前三季度营收为 2.25亿元，同比增长2.31%；净利润为883.67万元，同比增长15.82%。 ...

Core Insights - The stock of Maide Medical (688310) closed at 20.9 yuan on October 24, 2025, with a 1.36% increase and a trading volume of 19,500 lots, amounting to a total transaction value of 40.54 million yuan [1] Financial Performance - For the first half of 2025, Maide Medical reported a main revenue of 141 million yuan, a year-on-year decrease of 14.75% - The net profit attributable to shareholders was 6.0451 million yuan, down 38.81% year-on-year - The non-recurring net profit was -2.5149 million yuan, a decline of 135.52% year-on-year - In Q2 2025, the company achieved a single-quarter main revenue of 101 million yuan, an increase of 10.58% year-on-year - The single-quarter net profit attributable to shareholders was 16.8424 million yuan, a significant increase of 2759.64% year-on-year - The single-quarter non-recurring net profit was 11.8767 million yuan, up 923.08% year-on-year [3] Market Position - Maide Medical's total market capitalization is 3.474 billion yuan, compared to the industry average of 7.749 billion yuan, ranking 188 out of 268 in the specialized equipment industry - The company's net assets stand at 828 million yuan, with an industry average of 2.253 billion yuan, ranking 200 out of 268 - The net profit of 6.0451 million yuan places the company at 193 out of 268 in the industry, with a price-to-earnings ratio of 287.34, significantly higher than the industry average of 51.37, ranking 191 out of 268 - The price-to-book ratio is 4.34, compared to the industry average of 3.97, ranking 169 out of 268 - The gross margin is 38.93%, above the industry average of 27.83%, ranking 43 out of 268 - The net margin is -1.29%, below the industry average of 0.66%, ranking 215 out of 268 - The return on equity (ROE) is 0.76%, compared to the industry average of 2.21%, ranking 190 out of 268 [3] Investment Sentiment - In the last 90 days, one institution has given a rating of "buy" for Maide Medical [4]

Core Viewpoint - The stock of Maide Medical (688310) has shown a decline in price and mixed capital flow, indicating potential challenges in market performance and investor sentiment [1][2]. Financial Performance - As of October 22, 2025, Maide Medical's stock closed at 20.88 yuan, down 0.67% with a trading volume of 27,500 hands and a transaction amount of 57.62 million yuan [1]. - The company's main revenue for the first half of 2025 was 141 million yuan, a year-on-year decrease of 14.75%, while the net profit attributable to shareholders was 6.05 million yuan, down 38.81% year-on-year [3]. - The second quarter of 2025 showed a single-quarter main revenue of 101 million yuan, an increase of 10.58% year-on-year, and a net profit of 16.84 million yuan, up 2759.64% year-on-year [3]. Capital Flow Analysis - On October 22, 2025, the net inflow of main funds was 3.99 million yuan, accounting for 6.93% of the total transaction amount, while retail investors saw a net inflow of 2.47 million yuan, representing 4.29% of the total [1][2]. - Over the past five days, the stock has experienced fluctuations in capital flow, with significant net outflows from speculative funds on several days [2]. Industry Comparison - Maide Medical's total market value is 3.471 billion yuan, significantly lower than the industry average of 7.648 billion yuan, ranking 186 out of 268 in the specialized equipment industry [3]. - The company's price-to-earnings ratio (P/E) stands at 287.07, compared to the industry average of 48.9, indicating a high valuation relative to earnings [3]. - The gross profit margin of Maide Medical is 38.93%, which is above the industry average of 27.76%, but the net profit margin is negative at -1.29%, compared to a positive 0.54% industry average [3].

Group 1 - The core viewpoint of the news is that Maide Medical has seen a stock price increase of 5.16%, reaching 20.77 CNY per share, with a total market capitalization of 3.452 billion CNY [1] - Maide Medical, established on March 10, 2003, and listed on December 3, 2019, specializes in the research, production, sales, and service of medical consumables and intelligent equipment [1] - The company's main business revenue composition includes: 48.75% from safe infusion products, 26.27% from blood purification, and 24.98% from other categories [1] Group 2 - From the perspective of fund holdings, one fund under Guotai Fund has a significant position in Maide Medical, with 200,000 shares held, accounting for 1.08% of the fund's net value [2] - The Guotai Ju Li Value Flexible Allocation Mixed Fund (005746) has a current scale of 273 million CNY and has achieved a year-to-date return of 5.34% [2] - The fund's performance ranks 6799 out of 8243 in its category for the year and has a cumulative return of 46.8% since its inception [2]

Core Points - Midea Medical's stock price increased by 5.63% this week, closing at 20.07 yuan, with a market capitalization of 3.336 billion yuan [1] - The company reached a weekly high of 21.29 yuan and a low of 18.06 yuan [1] Company Announcements - Midea Medical will hold its first extraordinary general meeting of 2025 on October 30, 2025, to discuss two key proposals [2][3] - The first proposal includes the cancellation of the supervisory board, with the audit committee of the board taking over its responsibilities, and the removal of current supervisors [2][3] - The second proposal involves adjusting the board size from 7 to 8 members, adding one employee representative director, and revising various governance rules [2][3]

证券代码：688310 证券简称：迈得医疗 迈得医疗工业设备股份有限公司 2025 年第一次临时股东大会会议资料 二〇二五年十月 1 | 2025 年第一次临时股东大会会议须知 3 | | --- | | 2025 年第一次临时股东大会会议议程 6 | | 2025 年第一次临时股东大会会议议案 8 | | 议案一：关于取消监事会、调整董事会人数、修订《公司章程》并办理工商变更登记 | | 的议案 8 | | 议案二：关于修订及制定公司部分治理制度的议案 10 | 迈得医疗工业设备股份有限公司 2025 年第一次临时股东大会会议资料 迈得医疗工业设备股份有限公司 2025 年第一次临时股东大会会议须知 为维护全体股东的合法权益，确保股东大会会议秩序和议事效率，保证股东 大会的顺利召开，根据《中华人民共和国公司法》《中华人民共和国证券法》《上 市公司股东会规则》以及《迈得医疗工业设备股份有限公司章程》《迈得医疗工 业设备股份有限公司股东大会议事规则》等相关规定，特制定本会议须知： 一、公司负责本次股东大会的议程安排和会务工作，为确认出席大会的股东 或其代理人或其他出席者的出席资格，会议工作人员将对出席会议者的身 ...

证券之星消息，10月15日自动化设备板块较上一交易日上涨2.67%，迈得医疗领涨。当日上证指数报收 于3912.21，上涨1.22%。深证成指报收于13118.75，上涨1.73%。自动化设备板块个股涨跌见下表： | 代码 | 名称 | 主力净流入 (元) | 主力净占比 游资净流入 (元) | | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 300124 汇川技术 | | 1.02 Z | 3.22% | -8119.19万 | -2.55% | -2129.89万 | -0.67% | | 300024 | 机器人 | 3569.61万 | 4.02% | 1348.57万 | 1.52% | -4918.18万 | -5.54% | | 688698 伟创电气 | | 3471.99万 | 7.22% | -2030.96万 | -4.23% | -1441.04万 | -3.00% | | 688306 | 均普智能 | 2851.94万 | 5.28% | -1813.41万 | -3 ...

Core Insights - The medical consumables intelligent equipment industry is experiencing a dual upgrade in scale and quality, driven by the transformation of the manufacturing sector and the localization of medical devices [1][2] - Midea Medical Industrial Equipment Co., Ltd. (stock code: 688310) has over 20 years of experience in the medical consumables intelligent equipment sector, focusing on technological innovation and establishing core competitiveness in areas such as safe infusion and blood purification [1][2] Industry Overview - The Chinese medical device industry is projected to reach a total scale of 1.2 trillion yuan by 2025, with high-value consumables accounting for over 30%, corresponding to a market size exceeding 360 billion yuan [2] - The blood purification product segment is expected to grow significantly, with a market size of approximately 18.7 billion yuan in 2024, reflecting a year-on-year growth of 10% due to the rising number of end-stage renal disease (ESRD) patients [2] - The number of ESRD patients in China reached 4.1259 million in 2023 and is expected to increase to 5.2713 million by 2027, driving demand for automated production equipment for dialysis consumables [2] - The pre-filled syringe market is expanding rapidly, supported by the biopharmaceutical, medical aesthetics, and vaccine sectors, with a shift from Western markets to domestic production [2] - The "14th Five-Year" medical equipment industry development plan emphasizes support for the localization of high-end medical equipment, aiming for over 50% of county-level hospitals to procure domestic CTs by 2025 [2] Company Performance - Midea Medical focuses on intelligent equipment for medical consumables, including safe infusion, blood purification, and drug-device combination solutions, offering a full chain of solutions from single machines to connected systems [3] - The company has made significant advancements in blood purification equipment, breaking foreign monopolies with its domestically produced medical dialysis equipment [3] - Despite market fluctuations and longer production cycles, the company demonstrated resilience with R&D investment reaching 17.9772 million yuan, accounting for 12.75% of revenue, an increase of 0.48 percentage points year-on-year [4] - The net cash flow from operating activities reached 110 million yuan, a substantial year-on-year increase of 243.90%, indicating improved cash flow [4] Competitive Advantages - The company possesses strong core competencies across technology, R&D, customer relations, and market presence, with 18 key technologies, including advanced solvent bonding technology that reduces glue usage by 20% [5] - Midea Medical has established long-term partnerships with leading domestic medical consumables companies and has entered the supply chains of international clients [5] - The company has maintained the highest market share in its industry for three consecutive years from 2022 to 2024, showcasing its significant first-mover advantage [5] New Business Development - Midea Medical is expanding its growth avenues through its subsidiary, Midea Shun, which is focusing on the contact lens CDMO business, addressing domestic outsourcing gaps [6] - The company is also making strides in international markets by building overseas R&D and sales networks, aiming to extend its cost and technological advantages globally [6]